InsidersTradesSigma
Track the HOLOGIC INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, HOLOGIC INC has published 249 reports. Market capitalisation: €17bn. The latest transaction was reported on 9 April 2026 (Disposition). Among the most active insiders: MACMILLAN STEPHEN P. The full history is accessible without an account.
249
Insider Decl.
n/a
Thresholds
€266,013
1 ops.
Buy Volume
€7m
36 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HOLOGIC INC Hold (neutral), based on 9 analysts. Average price target: US$76.67.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,393 of 29,062 companies
57.0
score / 100
Value50
Quality64
FCF yld5.3%
Earn yld3.3%
EV/EBITDA17.8x
ROE11%
Gross mgn52%
Net mgn14%
Debt/EBITDA2.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 April 2026
Declarations249 total
25,784 sharesCommon StockSEC:0000859737-26-000077:0
23,026 sharesCommon StockSEC:0000859737-26-000081:0
28,052 sharesCommon StockSEC:0000859737-26-000083:0
4,932 sharesCommon StockSEC:0000859737-26-000069:0
7,371 sharesCommon StockSEC:0000859737-26-000071:0
50,526 sharesCommon StockSEC:0000859737-26-000073:0
8,358 sharesCommon StockSEC:0000859737-26-000075:0
17,964 sharesCommon StockSEC:0000859737-26-000059:0
15,370 sharesCommon StockSEC:0000859737-26-000061:1
7,603 sharesCommon StockSEC:0000859737-26-000079:0
6,626 sharesCommon StockSEC:0000859737-26-000061:0
16,146 sharesCommon StockSEC:0000859737-26-000063:0
5,445 sharesCommon StockSEC:0000859737-26-000067:1
1,423,837 sharesCommon StockSEC:0000859737-26-000065:0
1,146,829 sharesCommon StockSEC:0000859737-26-000065:1
5,396 sharesCommon StockSEC:0000859737-26-000067:0
77,694 sharesCommon StockSEC:0000859737-26-000085:0
150,735 sharesCommon StockSEC:0000859737-26-000087:0
41,462 sharesCommon StockSEC:0000859737-26-000089:0
17,644 sharesCommon StockSEC:0000859737-26-000091:0
134,039 sharesCommon StockSEC:0000859737-26-000093:0
185 shares@ US$75.3622.8% of flowCommon StockSEC:0000859737-26-000033:0
3,190 sharesCommon StockSEC:0000859737-26-000031:0
3,190 sharesCommon StockSEC:0000859737-26-000029:0
3,190 sharesCommon StockSEC:0000859737-26-000027:0
25 of 249 declarations
关于 HOLOGIC INC
Hologic Inc.（股票代码：HOLX）是一家总部位于美国的医疗技术公司，专注于女性健康，曾在美国纳斯达克市场上市。Hologic 总部位于马尔堡，马萨诸塞州，成立于 1985 年，其业务围绕经过临床验证的技术构建，这些技术支持女性健康路径中的筛查、诊断和治疗。其商业模式结合了经常性消耗品、已安装设备和创新驱动的产品升级，使其成为一个差异化的医疗技术平台，而非纯粹的诊断公司。([hologic.com](https://www.hologic.com/about?utm_source=openai)) Hologic 通过四个主要部门报告其运营：诊断、乳腺健康、妇科手术和骨骼健康。诊断部门包括用于疾病筛查和检测的分子检测和细胞学解决方案，在宫颈健康和性健康检测方面尤其强大。乳腺健康是公司的核心支柱之一，涵盖乳腺摄影系统、乳腺活检工具、定位技术以及从筛查到治疗的相关成像解决方案。妇科手术包括旨在解决异常子宫出血等妇科疾病的产品，而骨骼健康则涵盖骨密度测定和相关成像解决方案。这种多部门结构使 Hologic 拥有广泛的临床足迹，并有助于平衡医院、门诊和女性健康环境中的增长。([fintel.io](https://fintel.io/doc/sec-hologic-inc-859737-10k-2025-november-18-20410-6130?utm_source=openai)) 从竞争角度来看，Hologic 在女性健康诊断和乳腺成像领域占据重要地位，这得益于其知名品牌、庞大的装机量和全球商业网络。该公司表示，它在 36 个国家开展业务，拥有超过 4,100 项专利，这突显了其知识产权的深度以及其多个终端市场的进入壁垒。其竞争策略以精准、工作流程效率和临床信心为核心，并日益强调人工智能乳腺摄影和下一代活检解决方案。([hologic.com](https://www.hologic.com/about?utm_source=openai)) 最近的发展尤为重要。2025 年 10 月，Hologic 宣布与由 Blackstone 和 TPG 管理的基金达成最终协议，以每股最高 79 美元的价格被收购，该交易随后于 2026 年获得批准并完成，使公司私有化。公司还在 2025 年 2 月获得了其 Affirm Contrast Biopsy 软件的 CE 标志，并于 2025 年晚些时候继续扩展数字病理学能力。总而言之，这些事件表明，该公司在进入新的所有权结构的同时，仍然战略性地专注于女性健康创新。([investor.hologic.com](https://investor.hologic.com/press-releases/press-release-details/2025/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-79-per-Share/default.aspx?utm_source=openai))
